Under the agreement, each AstraZeneca project will involve either BioFocus or Argenta’s medicinal chemistry, biology and ADME/PK capabilities, and will also be able to access the full suite of in vivo respiratory pharmacology models of Argenta.
BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates for therapeutic areas such as neurodegenerative diseases and inflammatory diseases.
Financial terms of the deal have not been disclosed.
AstraZeneca is focused on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.